MedTrace Logo

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

NCT05975554 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-30

No results posted yet for this study

Summary

The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.

Conditions

  • TIA
  • Carotid Artery Plaque
  • Carotid Atherosclerosis

Interventions

DRUG

Interleukin-2 [IL-2]

5 sequential days of treatment (1.5MIU/day subcutaneously)

PROCEDURE

Standard care - Carotid Endarterectomy

Standard care for patients with carotid stenosis undergoing carotid endarterectomy

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-26
Primary Completion
2025-02-01
Completion
2025-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05975554 on ClinicalTrials.gov